283 related articles for article (PubMed ID: 37143472)
21. Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma.
Yang D; He Y; Wu B; Liu R; Wang N; Wang T; Luo Y; Li Y; Liu Y
Cancer Biomark; 2020; 29(3):399-416. PubMed ID: 32741804
[TBL] [Abstract][Full Text] [Related]
22. Identification of a pyroptosis-related lncRNA signature in the regulation of prognosis, metabolism signals and immune infiltration in lung adenocarcinoma.
Zhou S; Cai Y; Xu Z; Peng B; Liang Q; Peng J; Yan Y
Front Endocrinol (Lausanne); 2022; 13():964362. PubMed ID: 36034461
[TBL] [Abstract][Full Text] [Related]
23. A ferroptosis-related LncRNAs signature for predicting prognoses and screening potential therapeutic drugs in patients with lung adenocarcinoma: A retrospective study.
Dong J; Tao T; Yu J; Shan H; Liu Z; Zheng G; Li Z; Situ W; Zhu X; Li Z
Cancer Rep (Hoboken); 2024 Jan; 7(1):e1925. PubMed ID: 38043920
[TBL] [Abstract][Full Text] [Related]
24. Six MicroRNA Prognostic Models for Overall Survival of Lung Adenocarcinoma.
Li J; Gu X; Gao C; Zhang J
Genet Res (Camb); 2022; 2022():5955052. PubMed ID: 36101742
[TBL] [Abstract][Full Text] [Related]
25. Novel immunogenic cell death-related risk signature to predict prognosis and immune microenvironment in lung adenocarcinoma.
Li Q; Tang Y; Wang T; Zhu J; Zhou Y; Shi J
J Cancer Res Clin Oncol; 2023 Jan; 149(1):307-323. PubMed ID: 36575346
[TBL] [Abstract][Full Text] [Related]
26. A seven-long noncoding RNA signature predicts relapse in patients with early-stage lung adenocarcinoma.
Zhou H; Zhang H; Chen J; Cao J; Liu L; Guo C; Huang G; Zeng D
J Cell Biochem; 2019 Sep; 120(9):15730-15739. PubMed ID: 31050375
[TBL] [Abstract][Full Text] [Related]
27. A disulfidptosis-related lncRNA signature for predicting prognosis and evaluating the tumor immune microenvironment of lung adenocarcinoma.
Song Z; Cao X; Wang X; Li Y; Zhang W; Wang Y; Chen L
Sci Rep; 2024 Feb; 14(1):4621. PubMed ID: 38409243
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.
Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X
BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698
[TBL] [Abstract][Full Text] [Related]
29. Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung.
Miao H; Chen D; Li R; Hu J; Chen Y; Xu C; Wen Z
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33324975
[TBL] [Abstract][Full Text] [Related]
30. A more novel and powerful prognostic gene signature of lung adenocarcinoma determined from the immune cell infiltration landscape.
Ma C; Li F; He Z; Zhao S
Front Surg; 2022; 9():1015263. PubMed ID: 36311939
[TBL] [Abstract][Full Text] [Related]
31. Identification and validation of a novel redox-related lncRNA prognostic signature in lung adenocarcinoma.
Ren J; Wang A; Liu J; Yuan Q
Bioengineered; 2021 Dec; 12(1):4331-4348. PubMed ID: 34338158
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma.
Wang Y; Xu J; Fang Y; Gu J; Zhao F; Tang Y; Xu R; Zhang B; Wu J; Fang Z; Li Y
Front Immunol; 2022; 13():950001. PubMed ID: 36091041
[TBL] [Abstract][Full Text] [Related]
33. A neutrophil extracellular traps-related classification predicts prognosis and response to immunotherapy in colon cancer.
Feng C; Li Y; Tai Y; Zhang W; Wang H; Lian S; Jin-Si-Han EE; Liu Y; Li X; Chen Q; He M; Lu Z
Sci Rep; 2023 Nov; 13(1):19297. PubMed ID: 37935721
[TBL] [Abstract][Full Text] [Related]
34. A signature based on neutrophil extracellular trap-related genes for the assessment of prognosis, immunoinfiltration, mutation and therapeutic response in hepatocellular carcinoma.
Wang L; Wang Q; Li Y; Qi X; Fan X
J Gene Med; 2024 Jan; 26(1):e3588. PubMed ID: 37715643
[TBL] [Abstract][Full Text] [Related]
35. Construction of an immune-related lncRNA signature pair for predicting oncologic outcomes and the sensitivity of immunosuppressor in treatment of lung adenocarcinoma.
Zhuang J; Chen Z; Chen Z; Chen J; Liu M; Xu X; Liu Y; Yang S; Hu Z; He F
Respir Res; 2022 May; 23(1):123. PubMed ID: 35562727
[TBL] [Abstract][Full Text] [Related]
36. Immunoprognostic model of lung adenocarcinoma and screening of sensitive drugs.
Liang P; Li J; Chen J; Lu J; Hao Z; Shi J; Chang Q; Zeng Z
Sci Rep; 2022 May; 12(1):7162. PubMed ID: 35504892
[TBL] [Abstract][Full Text] [Related]
37. Integrated analysis of hypoxia-associated lncRNA signature to predict prognosis and immune microenvironment of lung adenocarcinoma patients.
Shao J; Zhang B; Kuai L; Li Q
Bioengineered; 2021 Dec; 12(1):6186-6200. PubMed ID: 34486476
[TBL] [Abstract][Full Text] [Related]
38. A signature of tumor DNA repair genes associated with the prognosis of surgically-resected lung adenocarcinoma.
Yang X; Wang G; Gu R; Xu X; Zhu G
PeerJ; 2020; 8():e10418. PubMed ID: 33304656
[TBL] [Abstract][Full Text] [Related]
39. Identification of 5-Gene Signature Improves Lung Adenocarcinoma Prognostic Stratification Based on Differential Expression Invasion Genes of Molecular Subtypes.
Zheng Z; Deng W; Yang J
Biomed Res Int; 2020; 2020():8832739. PubMed ID: 33490259
[TBL] [Abstract][Full Text] [Related]
40. Construction and validation of a T cell proliferation regulator-related signature for predicting prognosis and immunotherapy response in lung adenocarcinoma.
Chang W; Li H; Cheng Y; He H; Ou W; Wang SY
Front Immunol; 2023; 14():1171145. PubMed ID: 37081889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
